Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 11990 | 7.95 |
09:34 ET | 21067 | 8.022 |
09:36 ET | 109099 | 8.03 |
09:38 ET | 21308 | 8.0473 |
09:39 ET | 19392 | 8.1 |
09:41 ET | 16454 | 8.05 |
09:43 ET | 5145 | 8.08 |
09:45 ET | 11564 | 8.115 |
09:48 ET | 5060 | 8.08 |
09:50 ET | 2270 | 8.09 |
09:52 ET | 5211 | 8.12 |
09:54 ET | 27493 | 8.165 |
09:56 ET | 22340 | 8.1877 |
09:57 ET | 18530 | 8.1901 |
09:59 ET | 56031 | 8.23 |
10:01 ET | 23223 | 8.26 |
10:03 ET | 12849 | 8.225 |
10:06 ET | 9980 | 8.25 |
10:08 ET | 21682 | 8.21 |
10:10 ET | 2734 | 8.24 |
10:12 ET | 6891 | 8.1605 |
10:14 ET | 1734 | 8.18 |
10:15 ET | 7411 | 8.19 |
10:17 ET | 4111 | 8.185 |
10:19 ET | 12884 | 8.16 |
10:21 ET | 12757 | 8.23 |
10:24 ET | 11699 | 8.25 |
10:26 ET | 12362 | 8.22 |
10:28 ET | 36770 | 8.28 |
10:30 ET | 6502 | 8.28 |
10:32 ET | 10354 | 8.3 |
10:33 ET | 18265 | 8.275 |
10:35 ET | 5891 | 8.255 |
10:37 ET | 6820 | 8.235 |
10:39 ET | 200 | 8.22 |
10:42 ET | 7123 | 8.17 |
10:44 ET | 3634 | 8.163 |
10:46 ET | 1001 | 8.164 |
10:48 ET | 12260 | 8.13 |
10:50 ET | 2123 | 8.1337 |
10:51 ET | 2948 | 8.17 |
10:53 ET | 3003 | 8.18 |
10:55 ET | 2941 | 8.19 |
10:57 ET | 2661 | 8.175 |
11:00 ET | 4822 | 8.19 |
11:02 ET | 4760 | 8.205 |
11:04 ET | 3420 | 8.2 |
11:06 ET | 1500 | 8.21 |
11:08 ET | 1700 | 8.22 |
11:09 ET | 7220 | 8.24 |
11:11 ET | 10060 | 8.16 |
11:13 ET | 600 | 8.17 |
11:15 ET | 2348 | 8.175 |
11:18 ET | 4795 | 8.15 |
11:20 ET | 2507 | 8.144 |
11:22 ET | 3763 | 8.18 |
11:24 ET | 18360 | 8.12 |
11:26 ET | 5352 | 8.1201 |
11:27 ET | 17190 | 8.07 |
11:29 ET | 9761 | 8.08 |
11:31 ET | 4904 | 8.02 |
11:33 ET | 9245 | 8.03 |
11:36 ET | 10851 | 7.9915 |
11:38 ET | 5399 | 7.95 |
11:40 ET | 1707 | 7.96 |
11:42 ET | 1238 | 7.945 |
11:44 ET | 9167 | 7.99 |
11:45 ET | 8600 | 7.96 |
11:47 ET | 1857 | 7.975 |
11:49 ET | 8408 | 7.97 |
11:51 ET | 26515 | 7.94 |
11:54 ET | 300 | 7.95 |
11:56 ET | 3985 | 7.935 |
11:58 ET | 6065 | 7.98 |
12:00 ET | 400 | 7.96 |
12:02 ET | 5593 | 7.93 |
12:03 ET | 1499 | 7.92 |
12:05 ET | 15589 | 7.96 |
12:07 ET | 7293 | 7.97 |
12:09 ET | 1800 | 7.95 |
12:12 ET | 8248 | 7.9799 |
12:14 ET | 4257 | 7.96 |
12:16 ET | 100 | 7.951 |
12:18 ET | 8320 | 8 |
12:20 ET | 600 | 8 |
12:21 ET | 700 | 7.99 |
12:23 ET | 500 | 8 |
12:25 ET | 3761 | 7.99 |
12:27 ET | 9500 | 8.005 |
12:30 ET | 4991 | 7.98 |
12:32 ET | 4913 | 7.99 |
12:34 ET | 952 | 8.02 |
12:36 ET | 1550 | 8.01 |
12:38 ET | 1053 | 8.03 |
12:39 ET | 3038 | 8.05 |
12:41 ET | 26293 | 8.09 |
12:43 ET | 3673 | 8.06 |
12:45 ET | 100 | 8.06 |
12:48 ET | 100 | 8.06 |
12:50 ET | 7502 | 8.05 |
12:52 ET | 1700 | 8.06 |
12:54 ET | 2461 | 8.07 |
12:57 ET | 4269 | 8.085 |
12:59 ET | 6240 | 8.04 |
01:01 ET | 1500 | 8.065 |
01:03 ET | 1251 | 8.05 |
01:06 ET | 415 | 8.0412 |
01:08 ET | 4034 | 8.085 |
01:10 ET | 2174 | 8.07 |
01:12 ET | 5011 | 8.1 |
01:14 ET | 2300 | 8.1 |
01:15 ET | 2400 | 8.08 |
01:17 ET | 2400 | 8.1 |
01:19 ET | 100 | 8.07 |
01:21 ET | 9199 | 8.08 |
01:24 ET | 1799 | 8.05 |
01:26 ET | 1445 | 8.04 |
01:28 ET | 2300 | 8.04 |
01:30 ET | 3950 | 8.06 |
01:32 ET | 2300 | 8.065 |
01:33 ET | 2900 | 8.06 |
01:35 ET | 1010 | 8.06 |
01:37 ET | 11580 | 8.04 |
01:39 ET | 516 | 8.03 |
01:42 ET | 1176 | 8.02 |
01:44 ET | 1268 | 8 |
01:46 ET | 220 | 8 |
01:48 ET | 800 | 8.01 |
01:50 ET | 3570 | 8.04 |
01:53 ET | 4205 | 8.03 |
01:55 ET | 1320 | 8.03 |
01:57 ET | 900 | 8.02 |
02:00 ET | 8047 | 8.045 |
02:02 ET | 3439 | 8.0499 |
02:04 ET | 3629 | 8.03 |
02:06 ET | 3802 | 8.06 |
02:08 ET | 700 | 8.07 |
02:09 ET | 1882 | 8.0797 |
02:11 ET | 1200 | 8.08 |
02:13 ET | 7161 | 8.07 |
02:15 ET | 1500 | 8.08 |
02:18 ET | 850 | 8.08 |
02:22 ET | 6551 | 8.08 |
02:24 ET | 1318 | 8.08 |
02:26 ET | 6122 | 8.04 |
02:27 ET | 5976 | 8.05 |
02:31 ET | 3891 | 8.04 |
02:33 ET | 87661 | 8.14 |
02:36 ET | 2651 | 8.1396 |
02:38 ET | 2410 | 8.15 |
02:40 ET | 26335 | 8.2 |
02:42 ET | 9272 | 8.17 |
02:44 ET | 13946 | 8.195 |
02:45 ET | 6223 | 8.2 |
02:47 ET | 16253 | 8.17 |
02:49 ET | 7073 | 8.18 |
02:51 ET | 29261 | 8.19 |
02:54 ET | 74984 | 8.17 |
02:56 ET | 6607 | 8.15 |
02:58 ET | 11404 | 8.165 |
03:00 ET | 4165 | 8.175 |
03:02 ET | 1016 | 8.2 |
03:03 ET | 6361 | 8.18 |
03:05 ET | 2345 | 8.17 |
03:07 ET | 4898 | 8.18 |
03:09 ET | 6436 | 8.18 |
03:12 ET | 1907 | 8.17 |
03:14 ET | 26124 | 8.14 |
03:16 ET | 2900 | 8.12 |
03:18 ET | 5549 | 8.145 |
03:20 ET | 6701 | 8.11 |
03:21 ET | 1972 | 8.1 |
03:23 ET | 5047 | 8.14 |
03:25 ET | 14846 | 8.11 |
03:27 ET | 5141 | 8.1 |
03:30 ET | 5877 | 8.12 |
03:32 ET | 4009 | 8.135 |
03:34 ET | 2786 | 8.14 |
03:36 ET | 1000 | 8.13 |
03:38 ET | 1587 | 8.12 |
03:39 ET | 7953 | 8.11 |
03:41 ET | 15894 | 8.115 |
03:43 ET | 11736 | 8.11 |
03:45 ET | 5559 | 8.11 |
03:48 ET | 1631 | 8.12 |
03:50 ET | 9048 | 8.09 |
03:52 ET | 8868 | 8.115 |
03:54 ET | 8657 | 8.105 |
03:56 ET | 9241 | 8.125 |
03:57 ET | 29746 | 8.14 |
03:59 ET | 40150 | 8.14 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 5.5B | -49.1x | --- |
Viking Therapeutics Inc | 5.8B | -59.5x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.1x | --- |
Krystal Biotech Inc | 5.2B | 96.8x | --- |
Nuvalent Inc | 4.9B | -31.3x | --- |
BridgeBio Pharma Inc | 4.7B | -7.8x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.5B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.98 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -49.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.